Advertisement

Head and Neck Radiation Therapy

From Consultation to Survivorship and Future Directions
Published:March 03, 2022DOI:https://doi.org/10.1016/j.suc.2021.12.004

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Surgical Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Head and Neck Cancers Version 3.2021.
        (Available at:) (Accessed January 1, 2022)
        • Precise Bite Patient Re-Positioner
        Precise bite patient re-positioner. (n.d.).
        (Available at:) (Accessed January 1, 2022)
        • Stieb S.
        • Perez-Martinez I.
        • Mohamed A.S.R.
        • et al.
        The impact of tongue-deviating and tongue-depressing oral stents on long-term radiation-associated symptoms in oropharyngeal cancer survivors.
        Clin translational Radiat Oncol. 2020; 24: 71-78
        • Grégoire V.
        • Evans M.
        • Le Q.T.
        • et al.
        Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiotherapy and oncology.
        J Eur Soc Ther Radiol Oncol. 2018; 126: 3-24
        • Lee A.W.
        • Ng W.T.
        • Pan J.J.
        • et al.
        International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma.
        Radiother Oncol. 2018; 126: 25-36
      2. Tata Medical Center RSNA AVARO anatomy project. econtour.org. (n.d.).
        (Available at:) (Accessed January 1, 2022)
        • Ramasamy S.
        • Murray L.J.
        • Cardale K.
        • et al.
        Quality assurance peer review of head and neck contours in a large cancer centre via a weekly meeting approach.
        Clin Oncol (Royal Coll Radiol). 2019; 31: 344-351
        • Fong C.
        • Sanghera P.
        • Good J.
        • et al.
        Implementing head and neck contouring peer review without pathway delay: the on-demand approach.
        Clin Oncol (R Coll Radiol). 2017; 29: 841-847
        • Zairis S.
        • Margalit D.N.
        • Royce T.J.
        • et al.
        Prospective analysis of radiation oncology image and plan-driven peer review for head and neck cancer.
        Head Neck. 2017; 39: 1603-1608
        • Bar Ad V.
        • Weinstein G.
        • Dutta P.R.
        • et al.
        Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy.
        Head Neck. 2010; 32: 173-177
        • Milazzo-Kiedaisch C.A.
        • Itano J.
        • Dutta P.R.
        Role of gabapentin in managing mucositis pain in patients undergoing radiation therapy to the head and neck.
        Clin J Oncol Nurs. 2016; 20: 623-628
        • Jayakrishnan R.
        • Chang K.
        • Ugurluer G.
        • et al.
        Doxepin for radiation therapy-induced mucositis pain in the treatment of oral cancers.
        Oncol Rev. 2015; 9: 290
        • van Imhoff L.C.
        • Kranenburg G.G.
        • Macco S.
        • Nijman N.L.
        • van Overbeeke E.J.
        • Wegner I.,.
        • Pothen A.J.
        Prognostic value of continued smoking on survival and recurrence rates in patients with head and neck cancer: A systematic review.
        Head & neck. 2016; 38: E2214-E2220
      3. NRG-HN003 Cisplatin, Intensity-Modulated radiation therapy, and Pembrolizumab in treating patients with stage III-IV head and neck squamous cell carcinoma.
        (Available at:) (Accessed January 1, 2022)
        • Bonner J.A.
        • Harari P.M.
        • Giralt J.
        • et al.
        Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
        N Engl J Med. 2006; 354: 567-578
        • Gillison M.L.
        • Trotti A.M.
        • Harris J.
        • et al.
        Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
        Lancet. 2019; 393: 40-50
      4. Radiation therapy with durvalumab or cetuximab in treating patients with locoregionally advanced head and neck cancer who cannot Take Cisplatin.
        (Available at:) (Accessed January 1, 2022)
      5. Dose-Escalated Hypofractionated Adaptive Radiotherapy for head and neck cancer.
        (Available at:) (Accessed January 1, 2022)
        • Yom S.S.
        • Torres-Saavedra P.
        • Caudell J.J.
        • et al.
        Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002).
        J Clin Oncol. 2021; 39: 956-965
      6. De-intensified radiation therapy with CHEMOTHERAPY (Cisplatin) or IMMUNOTHERAPY (NIVOLUMAB) in treating patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal cancer.
        (Available at:) (Accessed January 1, 2022)
        • Ferris R.L.
        • Flamand Y.
        • Weinstein G.S.
        • et al.
        Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311).
        J Clin Oncol. 2020; 38: 6500
        • Nichols A.C.
        • Theurer J.
        • Prisman E.
        • Read N.
        • Berthelet E.
        • Tran E.,.
        • Palma D.A.
        Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial.
        Lancet Oncol. 2019; 20: 1349-1359
        • Anderson C.M.
        • Lee C.M.
        • Saunders D.P.
        • et al.
        Phase IIb, Randomized, Double-Blind Trial of GC4419 versus placebo to reduce severe oral mucositis due to concurrent radiotherapy and cisplatin for head and neck cancer.
        J Clin Oncol. 2019; 37: 3256-3265
      7. Roman: A study to investigate the effects of gc4419 on radiation induced oral mucositis in patients with head/neck cancer.
        (Available at:) (Accessed January 1, 2022)
        • Tsai C.J.
        • McBride S.M.
        • Riaz N.
        • et al.
        Reducing the Radiation Therapy Dose Prescription for Elective Treatment Areas in Human Papillomavirus-Associated Oropharyngeal Carcinoma Being Treated With Primary Chemoradiotherapy at Memorial Sloan Kettering Cancer Center.
        Pract Radiat Oncol. 2019; 9: 98-101
        • Håkansson K.
        • Smulders B.
        • Specht L.
        • et al.
        Radiation dose-painting with protons vs. photons for head-and-neck cancer.
        Acta Oncol. 2020; 59: 525-533
      8. Study of proton versus photon beam radiotherapy in the treatment of head and neck cancer.
        (Available at:)